Advocacy intelligence hub — real-time data for patient organizations
Robert Spiera, MD — PHASE2, PHASE3
Blokhin's Russian Cancer Research Center
Assistance Publique - Hôpitaux de Paris — PHASE2
Pace University — NA
University of Pennsylvania — PHASE1, PHASE2
University of South Florida — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
TAVNEOS
Amgen
Tavneos
(avacopan)Orphan drugstandardChemoCentryx, Inc.
Complement 5a Receptor Antagonist [EPC]
12.1 Mechanism of Action Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. ...
Peter A Merkel, MD, MPH
University of Pennsylvania
📍 Tampa, Florida
Peter A. Merkel, MD, MPH, MD, MPH
University of Pennsylvania
📍 RADNOR, PA
David Jayne, MD, MD
Cambridge University Hospitals NHS Foundation Trust
📍 EDMOND, OK
David Jayne, MD
Cambridge University Hospitals NHS Foundation Trust
📍 EDMOND, OK
Michael Walsh, MD
McMaster University
Arielle Mendel, MD MSc
McGill University